TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02202447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1169
Description: PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC0652
Description: PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
Study: NCT04717505

Intervention type: OTHER
Intervention: Standardized Mini Mental Test
Description: Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.

Intervention type: OTHER
Intervention: Standardized Mini Mental Test
Description: Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
Study: NCT04182334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Tempo Music
Description: For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attention Control
Description: Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
Study: NCT01967134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
Study: NCT01967134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
Study: NCT03080675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrional blend of ingredients including vitamins and fish oil
Study: NCT02605915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
Study: NCT03080675

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT03520907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversalis Fascia Plane Block
Description: block will be performed under real-time ultrasound guidance
Study: NCT00378066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab, Capecitabine, Oxaliplatin
Study: NCT03520907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal/iliohypogastric Nerve Block
Description: block will be performed under real-time ultrasound guidance
Study: NCT03145207

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine patch
Description: lidocaine patch
Study: NCT03950271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
Description: 1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles.
Study: NCT02443558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface control of robotic arms.
Description: The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface control of robotic arms.
Description: The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface control of robotic arms.
Description: The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
Study: NCT02443558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface control of robotic arms.
Description: The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MERCURY v2.0 robotic arms
Description: MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MERCURY v2.0 robotic arms
Description: MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
Study: NCT01913886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSCs injection
Description: MSCs cells will be injected in two aliquots of 10 ml by catheterism
Study: NCT02618759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DSXS
Description: active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo treatment
Study: NCT02731872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo humidifier
Description: The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured.
Study: NCT03547388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moderate whole body hyperthermia using water-filtered IR-A-radiation
Description: four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
Study: NCT01853033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection
Study: NCT01959152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode
Study: NCT00805766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: (1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
Study: NCT00600756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Oral, once daily, tablets of 400 mg to 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral, once daily, tablets of 2 mg to 6 mg
Study: NCT02097355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TriVox for clinical care
Description: Use TriVox disease modules to manage patients
Study: NCT00094965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (SR96669)
Description: oxaliplatin in combination with FOLFOX4
Study: NCT04462809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment.
Study: NCT04120532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Rehabilitation
Description: Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
Study: NCT02689258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX- 011B (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo via injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011A
Description: HTX- 011A (bupivacaine/meloxicam) via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-002
Description: HTX-002 via combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine HCl
Description: Bupivacaine HCl via injection
Study: NCT03373383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.
Study: NCT02618759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo treatment
Study: NCT02998086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management
Description: Skills-based intervention designed to promote resilience resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management
Description: Skills-based intervention designed to promote resilience resources
Study: NCT00652561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
Study: NCT03373383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching Padsevonil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching Padsevonil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching Padsevonil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching Padsevonil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided matching Padsevonil.
Study: NCT03413553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant
Description: Patient will receive immediate implant alone.

Intervention type: DEVICE
Group type: OTHER
Intervention: immediate implant
Description: Patient will receive immediate implant alone.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: connective tissue graft
Description: patient will receive immediate implant with connective tissue graft and platelet rich fibrin

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: platelet rich fibrin
Description: patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
Study: NCT02067377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serum bovine immunoglobulin (SBI) medical food
Description: Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
Study: NCT01406899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Based Treatment
Description: Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
Study: NCT02067377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serum bovine immunoglobulin (SBI) medical food
Description: Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for serum bovine immunoglobulin)
Study: NCT03435965

Intervention type: DIAGNOSTIC_TEST
Intervention: AmnioQuickDuo+
Description: AmnioQuickDuo+ kit for detection of PROM

Intervention type: DIAGNOSTIC_TEST
Intervention: AmnioQuickDuo+
Description: AmnioQuickDuo+ kit for detection of PROM

Intervention type: DIAGNOSTIC_TEST
Intervention: AmnioQuickDuo+
Description: AmnioQuickDuo+ kit for detection of PROM
Study: NCT01540058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Type ID test
Description: CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No test Empiric strategy
Description: Empiric strategy
Study: NCT03392116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM120
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT03184181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPTE® group
Description: Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling group
Description: The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
Study: NCT03364296

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Samples
Description: Blood sample retrieved for biological assessment and biobanking
Study: NCT03774940

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: peripheric blood count
Description: preoperative peripheric blood count

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: peripheric blood count
Description: preoperative peripheric blood count
Study: NCT03823248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoLuoDan
Description: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanchi powder
Description: oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid Tablet
Description: oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoLuoDan simulation
Description: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanchi powder simulation
Description: oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid Tablet simulation
Description: oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
Study: NCT02495311

Intervention type: PROCEDURE
Intervention: myomectomy or adenomyomectomy

Intervention type: PROCEDURE
Intervention: myomectomy or adenomyomectomy
Study: NCT00314236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BST-CarGel with Microfracture
Description: Microfracture performed with BST-CarGel added to the treated defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture without BST-CarGel
Description: Microfracture performed without BST-CarGel added to the treated defect.